Skip to main content

Table 3 Time dependent discontinue rate in treatment group compared with placebo

From: Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials

 3 month6 month12 month
Placebo9.28%16.78%N/A
Treatment5.74%14.24%22.22%
  1. N/A Not Applicable
\